Mark Zuckerberg & Priscilla Chan: How AI Will Cure All Disease

Summary

• The Biohub thesis is that shared scientific tools—not another round of small grants—are the highest-leverage route to faster cures. Mark Zuckerberg said major breakthroughs usually follow new ways to observe phenomena, yet tools such as imaging systems and virtual-cell models can require $100 million to $1 billion over 10–15 years. “We’re not going to cure all diseases”; the strategy is to help the scientific community do it.
• AI changes the timetable only if frontier models and frontier biology form a closed data flywheel. Biohub intends to design experiments and instruments around model blind spots, generate purpose-built data, retrain the models, and repeat. That bridges a striking cultural split: biologists considered curing disease “crazy ambitious,” while AI researchers thought it was “kind of boring—that’s just automatically going to happen.”
• CELLxGENE demonstrates how open infrastructure can acquire a network effect larger than its original funder. Built to clear an annotation bottleneck, it standardized formats and metadata across single-cell labs; CZI funded only 25% of the resulting resource, while the broader community contributed 75%. Vineeta Agarwala’s shorthand: “Come for the annotation, stay for the virtual cell model.”
• Virtual cells could expand biotechnology’s risk budget before expensive wet-lab work begins. Vineeta Agarwala argued that even directional predictions could let researchers test bolder hypotheses in silico before costly experiments, without risking years of work, publication, or tenure. Zuckerberg likened the model to “the new fruit fly” and said a perfect simulation is unnecessary; a directional signal could still be useful. The ambition is human-relevant modeling, tempered by the maxim: “All models are wrong. Some are useful.”
• Precision medicine here means treating common diseases as collections of individually rare biology. Chan’s framing was categorical: “Most diseases should be thought of as rare diseases,” because today’s hypertension and depression treatments still rely heavily on trial and error. Connecting a mutation to downstream cells, protein expression, drug targets, and predicted off-target effects could enable more precise diagnostics and therapies.
• CZI is concentrating its philanthropy around a unified operating Biohub that combines AI, data generation, and biological research. EvolutionaryScale researchers who formerly worked at Meta on protein-folding models are joining a Biohub, with its leader set to run the broader science program. Chan said, “The Biohub is really going to be the main thrust of our philanthropy,” while education and local-community work continue. They did not present centralization as a model for all science; decentralized work and outside labs remain important.
• The next laboratory expansion is computational: Biohub plans to move from roughly 1,000 GPUs toward the 10,000 range. Outside scientists can apply to use that capacity for questions individual labs—with only tens of GPUs—cannot tackle. As Zuckerberg put the allocation constraint, “The GPUs are somewhat zero-sum. The data isn’t.”

Deep dive

Not yet available upstream; scheduled sync will retry.